Human Dectin-1 is O-glycosylated and serves as a ligand for C-type lectin receptor CLEC-2

  1. Shojiro Haji
  2. Taiki Ito
  3. Carla Guenther
  4. Miyako Nakano
  5. Takashi Shimizu
  6. Daiki Mori
  7. Yasunori Chiba
  8. Masato Tanaka
  9. Sushil K Mishra
  10. Janet A Willment
  11. Gordon D Brown
  12. Masamichi Nagae  Is a corresponding author
  13. Sho Yamasaki  Is a corresponding author
  1. Kyushu University, Japan
  2. Osaka University, Japan
  3. Hiroshima University, Japan
  4. Centre National de la Recherche Scientifique, France
  5. National Institute of Advanced Industrial Science and Technology, Japan
  6. Tokyo University of Pharmacy and Life Sciences, Japan
  7. University of Mississippi, United States
  8. University of Exeter, United Kingdom

Abstract

C-type lectin receptors (CLRs) elicit immune responses upon recognition of glycoconjugates present on pathogens and self-components. While Dectin-1 is the best-characterized CLR recognizing b-glucan on pathogens, the endogenous targets of Dectin-1 are not fully understood. Herein, we report that human Dectin-1 is a ligand for CLEC-2, another CLR expressed on platelets. Biochemical analyses revealed that Dectin-1 is a mucin-like protein as its stalk region is highly O-glycosylated. A sialylated core 1 glycan attached to the EDxxT motif of human Dectin-1, which is absent in mouse Dectin-1, provides a ligand moiety for CLEC-2. Strikingly, the expression of human Dectin-1 in mice rescued the lethality and lymphatic defect resulting from a deficiency of Podoplanin, a known CLEC-2 ligand. This finding is the first example of an innate immune receptor also functioning as a physiological ligand to regulate ontogeny upon glycosylation.

Data availability

Sequencing data have been deposited in GEO under accession code GSE196049.

The following data sets were generated

Article and author information

Author details

  1. Shojiro Haji

    Department of Molecular Immunology, Kyushu University, Fukuoka, Japan
    Competing interests
    The authors declare that no competing interests exist.
  2. Taiki Ito

    Laboratory of Molecular Immunology, Osaka University, Osaka, Japan
    Competing interests
    The authors declare that no competing interests exist.
  3. Carla Guenther

    Laboratory of Molecular Immunology, Osaka University, Osaka, Japan
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7915-1028
  4. Miyako Nakano

    Graduate School of Integrated Sciences for Life, Hiroshima University, Hiroshima, Japan
    Competing interests
    The authors declare that no competing interests exist.
  5. Takashi Shimizu

    Laboratory of Molecular Immunology, Osaka University, Osaka, Japan
    Competing interests
    The authors declare that no competing interests exist.
  6. Daiki Mori

    Centre National de la Recherche Scientifique, Marseille, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Yasunori Chiba

    Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Ibaraki, Japan
    Competing interests
    The authors declare that no competing interests exist.
  8. Masato Tanaka

    Laboratory of Immune Regulation School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan
    Competing interests
    The authors declare that no competing interests exist.
  9. Sushil K Mishra

    Glycoscience Center of Research Excellence, University of Mississippi, Mississippi, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3080-9754
  10. Janet A Willment

    Medical Research Council Centre for Medical Mycology, University of Exeter, Exeter, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7040-0857
  11. Gordon D Brown

    Medical Research Council Centre for Medical Mycology, University of Exeter, Exeter, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  12. Masamichi Nagae

    Department of Molecular Immunology, Osaka University, Osaka, Japan
    For correspondence
    mnagae@biken.osaka-u.ac.jp
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5470-3807
  13. Sho Yamasaki

    Department of Molecular Immunology, Osaka University, Osaka, Japan
    For correspondence
    yamasaki@biken.osaka-u.ac.jp
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5184-6917

Funding

Japan Society for the Promotion of Science (20H00505)

  • Sho Yamasaki

Japan Society for the Promotion of Science (20K06575)

  • Masamichi Nagae

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Simon Yona, The Hebrew University of Jerusalem, Israel

Ethics

Animal experimentation: All animal protocols were approved by the committee of Ethics on Animal Experiment and Research Institute for Microbial Diseases, Osaka University (Permit number: Biken-AP-R03-17-0).

Human subjects: All human subjects research was approved by the Institutional Review Board of the Research Institute for Microbial Diseases, Osaka University. Informed consent and consent to publish were obtained from all individuals donating venous blood. Consent documents and procedures were approved by the Institutional Review Board of the Research Institute for Microbial Diseases, Osaka University (Permit number 29-12).

Version history

  1. Received: August 28, 2022
  2. Preprint posted: September 4, 2022 (view preprint)
  3. Accepted: December 7, 2022
  4. Accepted Manuscript published: December 8, 2022 (version 1)
  5. Version of Record published: December 23, 2022 (version 2)

Copyright

© 2022, Haji et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,218
    views
  • 227
    downloads
  • 5
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Shojiro Haji
  2. Taiki Ito
  3. Carla Guenther
  4. Miyako Nakano
  5. Takashi Shimizu
  6. Daiki Mori
  7. Yasunori Chiba
  8. Masato Tanaka
  9. Sushil K Mishra
  10. Janet A Willment
  11. Gordon D Brown
  12. Masamichi Nagae
  13. Sho Yamasaki
(2022)
Human Dectin-1 is O-glycosylated and serves as a ligand for C-type lectin receptor CLEC-2
eLife 11:e83037.
https://doi.org/10.7554/eLife.83037

Share this article

https://doi.org/10.7554/eLife.83037

Further reading

    1. Cancer Biology
    2. Immunology and Inflammation
    Nicholas J Mullen, Surendra K Shukla ... Pankaj K Singh
    Research Article

    Pyrimidine nucleotide biosynthesis is a druggable metabolic dependency of cancer cells, and chemotherapy agents targeting pyrimidine metabolism are the backbone of treatment for many cancers. Dihydroorotate dehydrogenase (DHODH) is an essential enzyme in the de novo pyrimidine biosynthesis pathway that can be targeted by clinically approved inhibitors. However, despite robust preclinical anticancer efficacy, DHODH inhibitors have shown limited single-agent activity in phase 1 and 2 clinical trials. Therefore, novel combination therapy strategies are necessary to realize the potential of these drugs. To search for therapeutic vulnerabilities induced by DHODH inhibition, we examined gene expression changes in cancer cells treated with the potent and selective DHODH inhibitor brequinar (BQ). This revealed that BQ treatment causes upregulation of antigen presentation pathway genes and cell surface MHC class I expression. Mechanistic studies showed that this effect is (1) strictly dependent on pyrimidine nucleotide depletion, (2) independent of canonical antigen presentation pathway transcriptional regulators, and (3) mediated by RNA polymerase II elongation control by positive transcription elongation factor B (P-TEFb). Furthermore, BQ showed impressive single-agent efficacy in the immunocompetent B16F10 melanoma model, and combination treatment with BQ and dual immune checkpoint blockade (anti-CTLA-4 plus anti-PD-1) significantly prolonged mouse survival compared to either therapy alone. Our results have important implications for the clinical development of DHODH inhibitors and provide a rationale for combination therapy with BQ and immune checkpoint blockade.

    1. Immunology and Inflammation
    Hyereen Kang, Seong Woo Choi ... Myung-Shik Lee
    Research Article

    We studied lysosomal Ca2+ in inflammasome. Lipopolysaccharide (LPS) + palmitic acid (PA) decreased lysosomal Ca2+ ([Ca2+]Lys) and increased [Ca2+]i through mitochondrial ROS, which was suppressed in Trpm2-KO macrophages. Inflammasome activation and metabolic inflammation in adipose tissue of high-fat diet (HFD)-fed mice were ameliorated by Trpm2 KO. ER→lysosome Ca2+ refilling occurred after lysosomal Ca2+ release whose blockade attenuated LPS + PA-induced inflammasome. Subsequently, store-operated Ca2+entry (SOCE) was activated whose inhibition suppressed inflammasome. SOCE was coupled with K+ efflux whose inhibition reduced ER Ca2+ content ([Ca2+]ER) and impaired [Ca2+]Lys recovery. LPS + PA activated KCa3.1 channel, a Ca2+-activated K+ channel. Inhibitors of KCa3.1 channel or Kcnn4 KO reduced [Ca2+]ER, attenuated increase of [Ca2+]i or inflammasome activation by LPS + PA, and ameliorated HFD-induced inflammasome or metabolic inflammation. Lysosomal Ca2+ release induced delayed JNK and ASC phosphorylation through CAMKII-ASK1. These results suggest a novel role of lysosomal Ca2+ release sustained by ERlysosome Ca2+ refilling and K+ efflux through KCa3.1 channel in inflammasome activation and metabolic inflammation.